Evidence map›Paper›PMID 29287626›Full record

ArticleSchizophrenia research2018

A comparison of conversion rates, clinical profiles and predictors of outcomes in two independent samples of individuals at clinical high risk for psychosis in China.

Huijun Li, TianHong Zhang, LiHua Xu, YingYing Tang, HuiRu Cui, YanYan Wei, XiaoChen Tang, Kristen A Woodberry, Daniel I Shapiro, ChunBo Li and 2 more

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03932136 (Decreasing Risk of Psychosis by Sulforaphane), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03932136 phase3active not recruitingnot on this mapstarted 2019, after this paper: background citation

Decreasing Risk of Psychosis by Sulforaphane: Study Protocol for a Randomized, Double-blind, Placebo-controlled, Clinical Multicenter Trial (DROPS Trial)

TypeinterventionalSponsorShanghai Jiao Tong University School of MedicineRan2019 to 2026Enrolled300ConditionsClinical High Risk Syndrome of PsychosisArmsSulforaphane, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Huijun LiFlorida A&M University, Department of Psychology, Tallahassee, FL 32307, USA. Electronic address: huijun.li@famu.edu.
TianHong ZhangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China.
LiHua XuShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China.
YingYing TangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China.
HuiRu CuiShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China.
YanYan WeiShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China.
XiaoChen TangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China.
Kristen A WoodberryHarvard Medical School Department of Psychiatry, Beth Israel Deaconess Medical Center, 75 Fenwood Rd, Boston, MA 02115, USA.
Daniel I ShapiroEmory University, Department of Psychology, USA.
ChunBo LiShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China.
Larry J SeidmanHarvard Medical School Department of Psychiatry, Beth Israel Deaconess Medical Center, 75 Fenwood Rd, Boston, MA 02115, USA.
JiJun WangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, PR China. Electronic address: jijunwang27@163.com.

Funding

Identifying mechanisms of response to therapeutic intervention in clinical high risk (CHR) for psychosis: a bridge to treatmentR01MH111448 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LI, HUIJUN, NIZNIKIEWICZ, MARGARET A · 2016 to 2023
$4.4M
Innovative Intervention for Reducing Stress Reactivity and Risk for PsychosisK23MH102358 · NIMH · MAINEHEALTH · PI WOODBERRY, KRISTEN ANNE · 2014 to 2017
$722k
Enhancing Intervention of Attenuated Psychosis Syndrome with M-Health TechnologyR21MH113674 · NIMH · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI LI, HUIJUN, STONE, WILLIAM SETH · 2017 to 2018
$341k
Broadening the Investigation of Psychosis Prodrome to Different Cultural GroupsR21MH093294 · NIMH · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI LI, HUIJUN, SEIDMAN, LARRY J · 2012 to 2013
$249k
NIMH NIH HHS K23 MH102358NIMH NIH HHS R01 MH111448NIMH NIH HHS R21 MH093294NIMH NIH HHS R21 MH113674
6 · The paper itself

Abstract

objectiveIn a previous epidemiological study, we reported on the ascertainment and outcomes of "clinical high risk" (CHR) individuals at the Shanghai Mental Health Center (SMHC, "2011 cohort"). The current study compares demographic and clinical characteristics, including conversion rates, of this sample with a subsequently recruited, independent CHR sample and with published data from western samples.

methodA new sample of 100 CHR subjects ("2013 cohort") was selected based on screening and semi-structured interviews. Both studies used the Structured Interview for Prodromal Syndromes (SIPS) for CHR assessment and conducted a naturalistic two-year follow-up. The two cohorts were compared on conversion rates, demographic and clinical characteristics, psychosis risk symptoms, and risk factors for psychotic conversion.

resultsNinety one (91%) of the 2013 cohort subjects completed the clinical two-year follow-up and 25 (27.5% of the 91) converted to a psychotic disorder over the follow-up period. A comparison of conversions to full psychosis between the 2013 and the 2011 cohorts showed no significant difference in time to conversion (Pairwise comparison: χ

conclusionsConversion rates in this new, independent Chinese sample are similar to those reported in non-Chinese samples and to the 2011 cohort. Future research is needed to examine whether the implementation of early intervention for CHR/prodromal symptoms reduces the risk of psychosis and decreases the conversion rate.

Indexed as

Disease ProgressionProdromal SymptomsAdolescentAdultChinaFemaleFollow-Up StudiesHumansMaleMiddle AgedPsychotic DisordersRiskYoung AdultClinical high riskConversion ratesProdromal psychosis

Identifiers

PMID29287626
PMCPMC6019611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.